Lyra Therapeutics, Inc. (LYRA)
NASDAQ$0.172
Market Cap
$11.26M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
693 of 924
Rank in Industry
396 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
LYRA Insider Trading Activity
LYRA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase …
Insider Activity of Lyra Therapeutics, Inc.
Over the last 12 months, insiders at Lyra Therapeutics, Inc. have bought $0 and sold $0 worth of Lyra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lyra Therapeutics, Inc. have bought $21.64M and sold $2.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $74,095 was made by Waksal Harlan (Executive Chair) on 2023‑11‑10.
List of Insider Buy and Sell Transactions, Lyra Therapeutics, Inc.
| 2023-11-10 | Waksal Harlan | Executive Chair | 25,000 0.0498% | $2.96 | $74,095 | -87.58% | ||
| 2023-05-31 | PERCEPTIVE ADVISORS LLC | 3.61M 9.5077% | $2.49 | $9M | +49.42% | |||
| 2023-05-31 | NBVM GP, LLC | 10 percent owner | 1.81M 4.6346% | $2.43 | $4.39M | +49.42% | ||
| 2023-05-31 | NBVM GP, LLC | 10 percent owner | 1.2M 3.0898% | $2.43 | $2.92M | +49.42% | ||
| 2023-05-31 | ANDERSON EDWARD T | 1.81M 4.6346% | $2.43 | $4.39M | +49.42% | |||
| 2022-06-10 | MERRIFIELD C ANN | 4,000 0.0119% | $5.05 | $20,200 | -35.30% | |||
| 2022-05-13 | MERRIFIELD C ANN | 328 0.001% | $5.00 | $1,640 | -19.36% | |||
| 2022-04-12 | EDELMAN JOSEPH | 5.92M 11.8975% | $4.22 | $25M | -21.89% | |||
| 2022-04-12 | ANDERSON EDWARD T | 1.08M 2.1626% | $4.22 | $4.54M | -21.89% | |||
| 2022-04-12 | North Bridge Venture Management VI, L.P. | 765,010 1.5364% | $4.22 | $3.23M | -21.89% | |||
| 2022-04-12 | Waksal Harlan | Executive Chair | 236,966 0.4759% | $4.22 | $999,997 | -21.89% | ||
| 2021-06-17 | MERRIFIELD C ANN | director | 3,500 0.0267% | $8.97 | $31,395 | -36.57% | ||
| 2020-12-16 | snyderman nancy lynn MD | director | 1,025 0.0118% | $9.72 | $9,963 | -14.25% | ||
| 2020-05-05 | Sale | Soleus Private Equity GP I, LLC | 10 percent owner | 33,818 0.3972% | $16.00 | $541,088 | -28.92% | |
| 2020-05-05 | Sale | NBVM GP, LLC | 10 percent owner | 48,366 0.568% | $16.00 | $773,856 | -28.92% | |
| 2020-05-05 | Sale | ANDERSON EDWARD T | 48,366 0.568% | $16.00 | $773,856 | -28.92% | ||
| 2020-05-05 | Sale | Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 9,674 0.1136% | $16.00 | $154,784 | -28.92% | |
| 2020-05-05 | PERCEPTIVE ADVISORS LLC | 1.25M 7.3399% | $8.00 | $10M | -28.92% | |||
| 2020-05-05 | Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 62,500 0.734% | $16.00 | $1M | -28.92% | ||
| 2020-05-05 | NBVM GP, LLC | 10 percent owner | 500,000 5.8719% | $16.00 | $8M | -28.92% |
Total: 22
Insider Historical Profitability
<0.0001%
| PERCEPTIVE ADVISORS LLC | 11469117 17.5214% | $1.97M | 2 | 0 | +10.25% | |
| EDELMAN JOSEPH | 7858285 12.0051% | $1.35M | 1 | 0 | <0.0001% | |
| ANDERSON EDWARD T | 2521745 3.8525% | $433,740.14 | 3 | 1 | <0.0001% | |
| NBVM GP, LLC | 10 percent owner | 2521745 3.8525% | $433,740.14 | 3 | 1 | +23.3% |
| North Bridge Venture Management VI, L.P. | 1318133 2.0137% | $226,718.88 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $11.34M | |
$1,724,269 | 63 | -16.36% | $12.25M | |
$1,159,104 | 40 | -21.75% | $7.98M | |
$383,884 | 32 | -25.10% | $12.65M | |
$95,303,339 | 30 | -13.78% | $10.77M |
LYRA Institutional Investors: Active Positions
| Increased Positions | 29 | +44.62% | 2M | +6.99% |
| Decreased Positions | 25 | -38.46% | 8M | -24.28% |
| New Positions | 9 | New | 1M | New |
| Sold Out Positions | 14 | Sold Out | 5M | Sold Out |
| Total Postitions | 69 | +6.15% | 27M | -17.29% |
LYRA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Perceptive Advisors Llc | $2,730.00 | 19.63% | 12.76M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $665.00 | 4.78% | 3.11M | +116,172 | +3.88% | 2024-12-31 |
| Samsara Biocapital, Llc | $421.00 | 3.02% | 1.97M | -814,572 | -29.3% | 2024-12-31 |
| Vanguard Group Inc | $383.00 | 2.75% | 1.79M | +8,159 | +0.46% | 2024-12-31 |
| Ikarian Capital, Llc | $226.00 | 1.63% | 1.06M | +1,319 | +0.13% | 2024-12-31 |
| Geode Capital Management, Llc | $190.00 | 1.36% | 885,966 | +117,578 | +15.3% | 2024-12-31 |
| Goldman Sachs Group Inc | $119.00 | 0.86% | 555,508 | +8,169 | +1.49% | 2024-12-31 |
| Adar1 Capital Management, Llc | $114.00 | 0.82% | 533,200 | +533,200 | New | 2024-12-31 |
| State Street Corp | $105.00 | 0.75% | 488,720 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $91.00 | 0.65% | 424,965 | +400,050 | +1,605.66% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.